Related Experiment Video
Updated: Sep 22, 2025
08:17
Dynamic Lung Tumor Tracking for Stereotactic Ablative Body Radiation Therapy
Published on: June 7, 2015
15.8K
Trials, Tribunals, and Opportunities for Lung Cancer KRASG12C Brain Metastases
Abstract:
The activity of KRAS inhibitors against brain metastases is relatively unexplored. The recent work on preclinical models and preliminary data from the ongoing KRYSTAL-1 phase Ib clinical trial support the potential of adagrasib (MRTX849) to penetrate the central nervous system and provide control of KRASG12C brain metastases. See related article by Sabari et al., p. 3318.
Insights
Adagrasib shows promise in treating KRAS G12C brain metastases. Early data suggest this KRAS inhibitor can enter the central nervous system and control tumor growth.
Area of Science:
- Oncology
- Neuro-oncology
- Pharmacology
Background:
- The efficacy of KRAS inhibitors in treating brain metastases remains largely uninvestigated.
- KRAS mutations are common in various cancers, including non-small cell lung cancer.
- Brain metastases represent a significant challenge in cancer patient management.
Discussion:
- Adagrasib (MRTX849) demonstrates potential for central nervous system (CNS) penetration.
- Preclinical models and early clinical data from the KRYSTAL-1 trial indicate adagrasib's activity against KRAS G12C brain metastases.
- This suggests a potential therapeutic option for patients with these specific metastases.
Key Insights:
- Adagrasib exhibits CNS penetration capabilities.
- Preliminary evidence supports adagrasib's efficacy in controlling KRAS G12C-mutated brain metastases.
- The KRYSTAL-1 trial provides early support for adagrasib's role in neuro-oncology.
Outlook:
- Further investigation is warranted to confirm adagrasib's role in managing brain metastases.
- Adagrasib could offer a new treatment avenue for patients with KRAS G12C-driven brain tumors.
- Ongoing research will elucidate the full therapeutic potential of adagrasib in CNS disease.
